'New Visiongain Report Shows Commercial Prospects for the 20 Leading Biopharmaceutical Companies' Says Recent Visiongain Study

LONDON, September 11, 2012 /PRNewswire/ --

A new report by visiongain assesses prospects for the leading 20 biopharma companies worldwide. Top pharmaceutical companies have consolidated their hold on the market by buying up most of the leading biotech products and platforms, according to Pharma Leader Series: Top 20 Biological Drug Manufacturers 2012-2022, published in September 2012.

Visiongain's study predicts revenues to 2022 for the leading companies and discusses their prospects. Roche continues to lead the market via its Genentech-developed biologics portfolio, but other multinationals are following. Top 10 players, according to the report's analysis, include Sanofi, which acquired Genzyme, GlaxoSmithKline, which this summer completed a takeover of Human Genome Sciences, and Pfizer, which bought Wyeth in 2009 to expand its capacities in vaccines and biologics.

Dr James Evans, a pharmaceutical industry analyst in visiongain, said: "The pharmaceutical industry is continuing to absorb the healthcare biotech industry. Amgen is still an independent biotech, but it is diversifying into generics, so the distinction between the two types of companies is being eroded from both sides. With biologics set to be the first, second and third bestselling pharmaceuticals of 2012, the competition for the biologics market is intense, and the coming of biosimilars is going to make it fiercer, by lowering the entry barriers for developing a biological drug.

"The biologics market is growing faster than the broader pharmaceutical market, and growth rates will be sustained through to 2022, our analyses show. Newer biological formats such as antibody-drug conjugates, therapeutic vaccines and cellular therapies will compensate for slowdown and contraction in areas such as erythropoietin and interferons. There will be hot competition in insulins, recombinant coagulating factors and mAbs, as companies battle for these lucrative market areas."

That new report forecasts that the biologics market will continue to expand rapidly to 2022, with leading pharma companies increasingly basing their growth strategies on opportunities in the biologics sector.

Visiongain is a business information provider based in London, UK. Pharma Leader Series: Top 20 Biological Drug Manufacturers 2012-2022 adds to that company's range of analytical reports on industries and markets in healthcare.
 

For sample pages and further information concerning the visiongain report Pharma Leader Series: Top 20 Biological Drug Manufacturers 2012-2022 please visit http://www.visiongain.com/Report/889/Pharma-Leader-Series-Top-20-Biological-Drug-Manufacturers-2012-2022

For an executive summary of this report please email:
Sara Peerun at sara.peerun@visiongainglobal.com
Tel: +44(0)20-7336-6100

Notes for Editors

Companies listed in this report include:

Abbott Laboratories
Abgenix
Ablynx
AC Immune
Acadia Pharmaceuticals
Acorda Therapeutics
Alantos Pharmaceuticals
ALK Abello
Allergan
Alnara Pharmaceuticals
Amgen
AstraZeneca
Avidia
Baxter International
Bayer HealthCare
Becton Dickinson
Biogen Idec
Bioheart
Biomira
BioVex
Boehringer Ingelheim
Bristol-Myers Squibb (BMS)
Cambridge Antibody Technologies
Centocor Ortho Biotech
Chinese Academy of Medical Sciences
Chinese Academy of Sciences
Chiron
Cilag Chemie
Coley Pharmaceuticals
Corixa
Cougar Biotechnology
CovX
Crucell Biotechnology
CSL Behring
CSL Biotherapies
CT Arztneimittel
Cytori
Dompé
Duke University
Dyax
Dynavax
Eisai
Elan
Eli Lilly
EMD Serono
Encysive Pharmaceuticals
ExonHit Therapeutics
Facet Biotech
Fresenius
F-Star
Galena Biopharma
Genentech
Genesis Pharma
Genetics Institute
Genmab
Genzyme
GlaxoSmithKline
GlycoFi
Grifols
GTC Biotherapeutics
HD Biosciences
Hexal
Hoechst Marion Roussel
Hospira
HudsonAlpha Institute for Biotechnology
Human Genome Sciences
Hutchison MediPharma
ID Biomedical
Ilypsa
ImClone
Immunex Corporation
ImmunoGen
Inspire Pharmaceuticals
Institute for Genomic Research
International Vaccine Institute
Ipsen
Janssen Pharmaceutica
Jiangsu Walvax Biotech Company
Johns Hopkins University
Johnson & Johnson
KAI Pharmaceuticals
Kinetix Pharmaceuticals
King
Knopp Neurosciences
Kuros
Kyorin Pharmaceutical
Kyowa Hakko Kirin
Lipoxen
Ludwig Institute for Cancer Research
McNeil Laboratories
Medarex
MedImmune
Medixion
Megapharm
Merck & Co.
Merck BioVentures
Merck KGaA
Merck-Banyu
Merz Pharma
Micromet
Millipore
Mitsubishi Tanabe Pharma
Molecular Partners
MorphoSys
Mustafa Nevzat Pharmaceuticals
National Center for Drug Screening (China)
Nestlé
Neurimmune SubOne
Novartis
Novo Nordisk
Oncothyreon
Ortho Pharmaceutical
Oxford University
Pasteur Merieux Serums & Vaccins
PDL BioPharma
Peptech
Pfizer
Pharmacia
Philogen
Pieris
Piramal
Portola Pharmaceuticals
PowderMed
Protein Design
Regeneron
Roche
Sabin Vaccine Institute
Samsung Biologics
Sandoz
Sanofi
Sanofi Pasteur MSD
Sanwa Kagaku Kenkyusho
Schering-Plough
Senju Pharmaceutical
Serenex
Shanghai ChemExplorer
Shanghai Institute of Biological Sciences
Shanghai Institute of Materia Medica
Shantha Biotechnics
Sirna Therapeutics
Solvay Pharmaceuticals
Swedish Orphan Biovitrum
Synergen
Synovis Life Technologies
Syntonix
Takeda
Talecris
Teva Pharmaceutical Industries
Tianjin Medical University Cancer Hospital
Transkaryotic Therapies
Trellis Bioscience
Trubion
Tularik
University of Queensland
Upjohn
Vaxdesign
Vernalis
VIVALis
Walter Reed Army Institute
Warner-Lambert
World Health Organization (WHO)
WuXi AppTec
Wyeth Pharmaceuticals
Zhejiang Taiyuan
Zydus Cadila
ZymoGenetics 

About visiongain

Visiongain is one of the fastest growing and most innovative independent business intelligence companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters and management reports focusing on the Energy, Telecoms, Pharmaceuticals, Defence, Aviation and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44(0)207-336-6100